New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
17:14 EDTAMGN, QGENAmgen announces FDA approval of Vectibix in combination with FOLFOX
Amgen (AMGN) announced that the FDA has approved Vectibix for use in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. With this approval, Vectibix becomes the first and only biologic to offer a significant survival benefit as a first-line treatment with FOLFOX, one of the most commonly used chemotherapy regimens in the first-line setting for patients with wild-type KRAS mCRC. In addition, this approval converts the accelerated monotherapy approval to a full approval for Vectibix. FDA also approved the therascreen KRAS RGQ PCR Kit developed by QIAGEN (QGEN) as a companion diagnostic for Vectibix.
News For AMGN;QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
09:20 EDTAMGNInsulet weakness creates buying opportunity, says Wedbush
Wedbush believes that Insulet's growth should accelerate as the year progresses, driven by increased adoption of its unique, programmable insulin pump and the launch of Amgen's (AMGN) Neulasta On-Body Delivery System.
April 15, 2015
18:56 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
17:06 EDTAMGNAmgen confirms FDA approval of Corlanor
Subscribe for More Information
16:40 EDTAMGNFDA approves Amgen's Corlanor to treat heart failure
Subscribe for More Information
April 6, 2015
08:22 EDTQGENBofA/Merrill life sciences analysts hold an analyst/industry conference call
Subscribe for More Information
05:19 EDTAMGNAmgen announces EC approval of Vectibix in combination with Folfiri
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use